Ketamine went from party drug to FDA-approved depression treatment inside a few decades, and the podcasts in our library have covered nearly every angle of that story: the accidental discovery, the glutamate science that displaced the serotonin hypothesis, the narrow dosing window between relief and anesthesia, and the addiction risk nobody likes to talk about at ketamine clinics.
We combed through our full catalog of episode summaries and pulled the eight conversations that actually teach you something about ketamine, not just repeat the same three talking points. Some are dedicated ketamine deep dives, others fold it into a bigger picture on depression, bipolar disorder, or psychedelic medicine generally. Every entry below is picked for a specific reveal you won't get from a headline.
All Things Ketamine — The Most Comprehensive Podcast Episode Ever with Dr. John Krystal
If you only listen to one ketamine episode, make it this one. Krystal is the Yale psychiatrist who actually discovered ketamine's rapid antidepressant effect, and he explains why psychiatry spent fifty years chasing serotonin and norepinephrine, which make up only about 2% of brain synapses, while ignoring glutamate, which runs roughly 90% of them. He walks through the narrow therapeutic window (0.5 mg/kg works, 0.2 mg/kg barely does anything, anesthetic doses kill the effect entirely) and doesn't dodge the addiction risk that gets glossed over elsewhere. Listen if you want the full scientific history from the person who wrote it.
Read the full episode notesKetamine: Benefits and Risks for Depression, PTSD & Neuroplasticity | Huberman Lab Podcast
Huberman's dedicated ketamine episode is the best single primer on mechanism: NMDA receptor blockade, BDNF mimicry, and a surprising role for the brain's opioid system. He cites the Stanford naltrexone study showing that blocking opioid receptors wipes out ketamine's antidepressant benefit while leaving the euphoria and dissociation untouched, which separates the trip from the cure. He also covers real-world dosing protocols, like twice-weekly infusions for three weeks producing relief that outlasts the drug itself. Good for anyone weighing a ketamine clinic and wanting the biology first.
Read the full episode notesThe Possibilities of Mind-Altering Compounds | Dr. Suresh Muthukumaraswamy | The Tim Ferriss Show
This one is for the skeptics. Muthukumaraswamy is a psychopharmacologist who ran a scopolamine antidepressant trial that found no effect once an active placebo was used, and he brings that same rigor to ketamine. He points out that ketamine's half-life is about four hours, so by 24 hours there's no drug left in the body, yet patients stay non-depressed, which he calls proof it flips a functional switch rather than just sedating people. He also flags that a vial of generic ketamine costs about $20 in New Zealand while the patented nasal spray Spravato runs $5,000 to $6,000 for comparable relief. Listen if you want the methodology and the pricing reality check.
Read the full episode notesPsychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
Williams runs Stanford's Brain Stimulation Lab and puts ketamine in context alongside TMS, psilocybin, MDMA, and ibogaine. The standout detail is the same naltrexone finding from the opioid angle, plus his broader argument that the serotonin 'chemical imbalance' theory is wrong since his TMS protocol works without touching serotonin at all. He also describes ibogaine as '10 years of psychotherapy in a night' for Navy SEALs processing moral injury. Good for listeners who want ketamine positioned against the rest of the psychedelic medicine toolkit.
Read the full episode notesEssentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
A tighter recut of the Williams conversation above, worth its own spot for the details it foregrounds: a single ketamine infusion's antidepressant effect lasts only about a week and a half on average, which is why repeat dosing is standard practice, not a red flag. It also spends more time on his SAINT/SNT transcranial magnetic stimulation protocol, which compresses six weeks of treatment into five days and pushes 60 to 90% of patients into remission. Listen if you want the shorter, denser version focused on how ketamine compares to non-drug alternatives.
Read the full episode notesUnderstanding & Conquering Depression
Huberman's broader depression episode places ketamine among a full stack of evidence-based tools, from EPA omega-3s (roughly 1000 mg can match SSRIs) to creatine's effect on the forebrain phosphocreatine system. Ketamine shows up specifically as an NMDA receptor blocker being used clinically despite sharing a mechanism with PCP, a drug of abuse. Useful for anyone who wants ketamine's place in a wider treatment plan rather than as a standalone fix.
Read the full episode notesThe Science & Treatment of Bipolar Disorder
Not a ketamine episode on its face, but it earns its place with one sharp contrast: lithium and ketamine sit at opposite ends of homeostatic plasticity, with lithium reducing neuronal excitability while ketamine increases it. Huberman also covers lithium's discovery through John Cade's guinea pig experiments and its 21-year wait for FDA approval because a naturally occurring element can't be patented. Worth it for anyone curious how ketamine's mechanism looks next to psychiatry's oldest mood stabilizer.
Read the full episode notesThe Psychedelic News Hour - New Breakthroughs, Treatment of Trauma, and More | The Tim Ferriss Show
Ferriss flips to the guest chair here, interviewed by two ketamine-assisted psychotherapists about the state of psychedelic medicine funding and research. The MDMA numbers are the hook: patients averaging 17 years of treatment-resistant PTSD saw 53% no longer meet diagnostic criteria after three doses plus therapy, and 67% still didn't at the five-year mark. Ferriss is candid that his answer to 'should I try a psychedelic' is no more than 90% of the time once he asks follow-up questions. Good for the funding and safety context around the whole field ketamine sits inside.
Read the full episode notesThat's eight ways into the ketamine conversation, from the lab bench to the clinic to the funding meetings that made the research possible. Browse the full episode summaries on Episode Notes for the rest of each conversation, timestamps included.